Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride. It exports its products to approximately 85 countries, including the United States, the European Union, and internationally. The company is based in Jingmen, China.
Research context
Hubei Biocause Pharmaceutical Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Financial Services
- Industry
- Insurance - Life
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Hubei Biocause Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 17.2% below its 200 day moving average.
From a valuation standpoint, the stock is 84.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.5.
Hubei Biocause Pharmaceutical Co., Ltd's total revenue rose by 26.1% to $3B since the same quarter in the previous year.
Its net income has dropped by 79.4% to $55M since the same quarter in the previous year.
Finally, its free cash flow grew by 12.7% to $4B since the same quarter in the previous year.
Based on the above factors, Hubei Biocause Pharmaceutical Co., Ltd gets an overall score of 3/5.